Dr. Millicent Overley Rovelo, MD

Dr. Rovelo practices at West Coast Wound and Skin Care Inc in Burbank, California.

Dr. Rovelo's NPI, 1326280371, was assigned on April 6, 2009. Dr. Rovelo graduated from Keck School of Medicine of USC in 2009. Dr. Rovelo holds California license A130080.

Dr. Rovelo's primary practice is West Coast Wound and Skin Care Inc, at 2501 W Burbank Blvd, Burbank, CA 91505 in Los Angeles County. The practice phone is (818) 856-9535.

Dr. Rovelo's primary practice is West Coast Wound and Skin Care Inc in Burbank, California. Dr. Rovelo is also affiliated with PIH Health Whittier Hospital. The medical group on file is West Coast Wound & Skin Care. Dmand AI also links Dr. Rovelo to 2 more group practices and clinics, 2 medical groups and 1 ambulatory surgery center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rovelo practices, 4 sites in all. Vendor and product names are available with a free account.

Plastic surgery is Dr. Rovelo's primary specialty in the NPI Registry, under taxonomy code 208200000X. Dr. Rovelo is board certified in plastic surgery by the American Board of Plastic Surgery. Dmand AI has Dr. Rovelo's licenses on file in 2 states: California and Louisiana.

Dmand AI lists breast reconstruction, chronic skin ulcer, head wound and lymphedema among the conditions Dr. Rovelo treats.

CMS data shows 12,327 Medicare services from Dr. Rovelo across 21 procedure codes in 2024, for 280 Medicare patients. Medicare paid $8,300,448 for them.

CMS counts 280 Medicare patients who saw Dr. Rovelo in 2024. The largest group is 85 and over, with 87 patients. 75% of them have high blood pressure, and 70% have high cholesterol. 53% are also on Medicaid. Their average risk score is 3.38, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Rovelo's median patient age at 60, with 60% women.

In 2024, Dr. Rovelo wrote 85 Medicare Part D claims for 35 patients. 100% of them were for generic drugs. CMS names the drug for 59 of them, across 3 drugs with 11 or more claims each, at $259 in total drug cost. In 2023, CMS named 45 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 79 out of 100 for Dr. Rovelo for performance year 2024, reported as part of a group. Dr. Rovelo accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Rovelo as offering telehealth. CMS counts 630 procedures of removal of tissue by Dr. Rovelo, more than 98% of the clinicians it reports for that procedure.

Mastectomy: 1 to 10 procedures (CMS shows small counts as a range)

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 1 paper to Dr. Rovelo in 2023. Dr. Rovelo's most frequent co-authors are Jay Calvert, MD and Pasha Shakoori, MD.

CMS Open Payments shows 62 general payments to Dr. Rovelo from 13 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 86% of the total. Allergan Inc. paid the most, $1,737.

Dmand AI lists 1 award for Dr. Rovelo.

Dr. Rovelo graduated from Keck School of Medicine of USC in 2009. Dr. Rovelo is a member of ACS, ASAPS and ASPS.

Dr. Rovelo is in network with 12 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 11. Check the plan with the practice before a visit.